http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김재홍,윤기범,박평원,김영진,전경민,김영태,김중환,곽호,구상완,송민석,유옥,지혜구,김동원,문상은,박영립,정승호,성범진,성순제,엄주용,황정열,이기홍,이주협,전태진 대한화학요법학회 1994 대한화학요법학회지 Vol.12 No.1
The prevalence of PPNG among pretreated gonorrhea cases isolated at the STD clinic of Choong-Ku Public Health Center in Seoul has been studied and reported annually since 1981. In 1991, 123 strains of N.gonorrhoeae were isolated, among which 58(47.1%) were PPNG. In 1992, 98 starains of N.gonorrhoeae were isolated, among which 51(52.0%) were PPNG. In all, 109(49.3%) strains were found to be PPNG among 221 strains isolated between 1991-1992. The prevalence of PPNG in Seoul showed increased tendency till 1989, thereafter, it has been stationary or slightly decreasing.
Case Report : Leflunomide-induced Toxic Epidermal Necrolysis in a Patient with Rheumatoid Arthritis
( Ji Hye Je ),( Hyun Jung Lee ),( Young Ju Na ),( Ji Hye Seo ),( Young Ho Seo ),( Jae Hoon Kim ),( Sung Jae Choi ),( Young Ho Lee ),( Jong Dae Ji ),( Gwan Gyu Song ) 대한류마티스학회 2014 대한류마티스학회지 Vol.21 No.6
Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998 and has been available in Korea since 2003. Allergic cutaneous reactions (rash, purpura) are common (<10%) side effects of leflunomide, but severe cases such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are rarely reported. There has not been a report of SJS or TEN induced by leflunomide in Korea. Here we report a case of leflunomide-induced TEN in a patient with rheumatoid arthritis. Leflunomide was discontinued, and the TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved over four weeks with residual post-inflammatory hyperpigmentation.
( Ji Hye Seo ),( Nam Hoon Kim ),( Dong Seop Choi ),( Sin Gon Kim ),( Hee Young Kim ),( Jee Hyun An ),( Sun Hwa Kim ),( Kyeong Jin Kim ),( Ji Hye Je ),( Young Ju Na ),( Hyun Jung Lee ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: L-thyroxine (LT4) withdrawal is a commonly used method prior to radioactive iodine (RAI) ablation treatment in differentiated thyroid cancer (DTC) patients. However, a prolonged period of hypothyroidism may reduce quality of life in DTC patients. Furthermore, LT4 withdrawal may have trophic effect on residual cancer by increased TSH and deteriorate cardiac function. We reported two cases of high-risk DTC patients with malignant pleural effusion who underwent rapidly worsening of the disease after LT4 withdrawal and RAI therapy. Patient findings: The first case involved a 65-year-old women who had papillary thyroid cancer with multiple distant metastases and malignant pleural effusion. During LT4 withdrawal for the RAI therapy, rapid worsening malignant pleural effusion required repetitive therapeutic thoracentesis. The second case involved a 49-yearold woman who had papillary thyroid cancer and had undergone three additional operations for neck lymph node cancer recurrences and four RAI treatments. During planning the 5th RAI therapy with LT4 withdrawal, malignant pleural effusion was developed, and it was progressively aggravated after RAI treatment. Both of two cases were high-risk patients accompanied with extra-thyroidal invasion and LN metastasis at the time of the diagnosis. Both experienced increased pleural effusion during the LT4 withdrawal period and a rise in the thyroglobulin level after RAI therapy. Malignant pleural effusion was not controlled with therapeutic thoracentesis and pleurodesis. Eventually, both of them came to death due to rapid disease progression after RAI treatment. Conclusion: LT4 withdrawal for RAI treatment may be harmful in high-risk DTC patients, especially with distant metastases and malignant pleural effusion.
( Ji Hye Je ),( Ji Hoon Kim ),( Yang Jae Yoo ),( Sung Hee Kang ),( Hae Rim Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Several staging systems for hepatocellular carcinoma (HCC) have been purposed but there is no worldwide consensus which staging system is best. We identifi ed the best staging system evaluating the predictive ability for outcome in patients with hepatocellular carcinoma in Korea. Methods: Between January 2004 and December 2009, total of 875 patients with HCC who were diagnosed and treated at the Korea University Guro hospital were enrolled. They were followed up till April 2014. All patients were classifi ed by modifi ed UICC, Barcelona-Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Chinese University Prognostic Index (CUPI), Japan Integrated Staging (JIS), Tokyo score. The demographic data, clinical variables, tumor characters, residual liver function and initial treatment modalities were reviewed. The discriminatory ability of staging system was quantifi ed using C-index. And the homogeneity and monotonicity of staging system was assessed using likelihood ratio χ2 test correlated with a Cox`s regression model neutralized by Akaike information criterion (AIC). Results: 654 (74. 7%) patients died and the median survival time was 25 months. The 5-years survival was 28. 1%. There were significant differences between all stage in modifi ed UICC, BCLC, CLIP, CUPI, JIS, Tokyo score. In the overall group of patients, CLIP stage had higher discrimination ability (C-index 0. 76) and the best monotonicity of gradient and homogeneity ability (LR χ2 test : 319. 541, P < 0. 008, AIC : 7789. 566). Also JIS system had higher discrimination ability (C-index 0. 75) and higher monotonicity of gradient and homogeneity ability (LR χ2 test : 320. 356, P<. 0001, AIC : 7792. 751). Conclusions: The CLIP and JIS stage systems showed the best prognostic stratifi cation in HCC patients of Korea.
( Ji Hye Seo ),( Ji Hye Je ),( Hyun Jung Lee ),( Young Ju Na ),( Il Woo Jeong ),( Jee Hyun An ),( Sin Gon Kim ),( Dong Seop Choi ),( Nam Hoon Kim ) 영남대학교 의과대학 2015 Yeungnam University Journal of Medicine Vol.32 No.2
L-thyroxine (LT4) withdrawal prior to radioactive iodine (RAI) ablation therapy is a commonly used method for successful treatment of patients with papillary thyroid cancer (PTC). However, a prolonged period of hypothyroidism induced by LT4 withdrawal is sometimes associated with impaired quality of life and cardiopulmonary dysfunction in PTC patients. Furthermore, LT4 withdrawal may have a trophic effect on residual cancer by means of increased thyrotropin. We report on 2 cases of metastatic PTC patients with malignant pleural effusion (MPE) whose disease showed rapid worsening after LT4 withdrawal and RAI therapy. The first case is a 65-year-old woman who had PTC with multiple distant metastases and MPE. During LT4 withdrawal for RAI therapy, MPE showed rapid worsening, and the patient required repetitive therapeutic thoracentesis. The second case is a 49-year-old woman with PTC who underwent 3 additional operations for cancer recurrence in the neck lymph nodes and 6 times of RAI treatments. While preparing for the 7th RAI treatment by withdrawing LT4, she developed MPE which became progressively aggravated after RAI therapy. Both patients experienced increased pleural effusion during the LT4 withdrawal period and a rise in the thyroglobulin level was observed after RAI therapy. MPE was not controlled with therapeutic thoracentesis and pleurodesis. Eventually, both patients died of rapid disease progression after RAI therapy. In summary, LT4 withdrawal may have an adverse effect on metastatic PTC patients, particularly those with MPE.
Doubling Time of Serum Tumor Marker in HCC Patients Predicts Recurrence after Curative Treatment
( Ji Hye Je ),( Yang Jae Yoo ),( Young-sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Alpha-fetoprotein (AFP) and protein-induced vitamin K absence (PIVKA-II) have been used as a marker for hepatocellular carcinoma (HCC). We aimed to investigate the correlation of doubling time (DT) of tumor markers (AFP, PIVKA-II) after curative treatment with recurrence of HCC. Methods: Between January 2005 and December 2013, total of 451 patients were enrolled. After excluding the patient with loss to follow- up, tumor remnant and absence of repeated tumor marker, 213 patients who received curative treatment were analyzed (Liver transplantation, surgical resection, radiofrequency ablation, percutaneous ethanol injection). Serum AFP and PIVKA II levels before and after the curative treatment were collected and used for analysis. Tumor marker DT was calculated as DT=t log 2/(log (marker 2nd)-log (marker 1st)) where t was the time interval between from nadir level after treatment to level at recurrence or 2 years later after treatment. Results: Mean age was 56 years. HBV infection was the most common etiology of HCC (78.4%), and most of the patients were in BCLC stage 0 and A (77.9%). During the follow up, 127 of 213 patients (59.6%) were recurred. Median DT of AFP and PIVKA-II was 20months and 18.7months. In comparing the HCC patients with or without early recurrence, DT was significantly lower in the early recurrence group (AFP and PIVKA II: 10.4 vs 26.78 months; P<0.001 and 8.75 vs 24.67 months; P<0.001, respectively). In univariate analysis, BCLC stage, tumor size, PIVKA-II level at diagnosis, AFP DT and PIVKA-II DT were significantly related to recurrence rate. In multivariate analysis, AFP DT and PIVKA-II DT and BCLC stage at diagnosis were only independent predictor of recurrence after curative treatment on HCC. Conclusions: In HCC patients with curative treatment, the DT of AFP and PIVKA-II from nadir level after the treatment is useful tools to predict early recurrence.
Antioxidant and neuroprotective activities of Sasa borealis extracts
Min Hye Kang(강민혜),Yun Jeong Ji(지윤정),Su Ji Choi(최수지),Seung Eun Lee(이승은),Je Hun Choi(최재훈),Gwi Yeong Jang(장귀영),Kyung Hye Seo(서경혜),Hyung Don Kim(김형돈) 한국약용작물학회 2021 한국약용작물학회 학술대회논문집 Vol.2021 No.1
Background : The Sasa borealis (SB), a species of bamboo, is a medicinal plant. It is known that SB has diverse biological activities like anti-diabetic, anti-obesity, anti-inflammatory, etc. This study was performed to investigate the antioxidant and neuroprotective activities of SB. Methods and Results : Sasa borealis (SB) aerial parts were extracted using distilled water and 70% ethanol respectively, producing SB water extract (SBW) and SB 70% ethanol extract (SBE). Antioxidant components, such as total phenolic contents (TPC) and total flavonoid contents (TFC), of the extracts were determined and antioxidant activities of the extracts were measured by in vitro assays including 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acd) (ABTS) and 2,2’-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity. The intracellular reactive oxygen species (ROS) levels in neuronal cells were detected by 2’,7’-dichlorofluorescin diacetate (DCF-DA) assay. While TPC of SBE was higher than SBW, TFC of SBW was higher than SBE. In ABTS<sup>+</sup> and DPPH radical scavenging assay, SBE showed higher scavenging activity than SBW. And all SB extracts (SBW, SBE) significantly reduced the H2O2-induced ROS production in neuronal cells. Conclusion : Sasa borealis (SB) water and ethanol extracts have good antioxidant activities and ameliorated the H2O2-induced ROS production in neuronal cells. This result indicates that SB extracts can be promising candidates for further researches designed to treat and manage neurological disorders.
Seo, Ji Hye,Je, Ji Hye,Lee, Hyun Jung,Na, Young Ju,Jeong, Il Woo,An, Jee Hyun,Kim, Sin Gon,Choi, Dong Seop,Kim, Nam Hoon Yeungnam University College of Medicine 2015 Yeungnam University Journal of Medicine Vol.32 No.2
L-thyroxine (LT4) withdrawal prior to radioactive iodine (RAI) ablation therapy is a commonly used method for successful treatment of patients with papillary thyroid cancer (PTC). However, a prolonged period of hypothyroidism induced by LT4 withdrawal is sometimes associated with impaired quality of life and cardiopulmonary dysfunction in PTC patients. Furthermore, LT4 withdrawal may have a trophic effect on residual cancer by means of increased thyrotropin. We report on 2 cases of metastatic PTC patients with malignant pleural effusion (MPE) whose disease showed rapid worsening after LT4 withdrawal and RAI therapy. The first case is a 65-year-old woman who had PTC with multiple distant metastases and MPE. During LT4 withdrawal for RAI therapy, MPE showed rapid worsening, and the patient required repetitive therapeutic thoracentesis. The second case is a 49-year-old woman with PTC who underwent 3 additional operations for cancer recurrence in the neck lymph nodes and 6 times of RAI treatments. While preparing for the $7^{th}$ RAI treatment by withdrawing LT4, she developed MPE which became progressively aggravated after RAI therapy. Both patients experienced increased pleural effusion during the LT4 withdrawal period and a rise in the thyroglobulin level was observed after RAI therapy. MPE was not controlled with therapeutic thoracentesis and pleurodesis. Eventually, both patients died of rapid disease progression after RAI therapy. In summary, LT4 withdrawal may have an adverse effect on metastatic PTC patients, particularly those with MPE.
Choi, Eun-Ji,Lee, Je-Hwan,Lee, Jung-Hee,Park, Han-Seung,Ko, Sun-Hye,Hur, Eun-Hye,Moon, Juhyun,Goo, Bon-Kwan,Kim, Yeonhee,Seol, Miee,Lee, Young-Shin,Kang, Young-Ah,Jeon, Mijin,Woo, Ji Min,Lee, Kyoo-Hyu Elsevier 2018 Leukemia research Vol.68 No.-
<P><B>Abstract</B></P> <P>This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed <I>FLT3</I>-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m<SUP>2</SUP>/d × 3d; n = 44), standard-dose daunorubicin (SD-DN; 45 mg/m<SUP>2</SUP>/d × 3d; n = 51), or idarubicin (IDA; 12 mg/m<SUP>2</SUP>/d × 3d; n = 33) in combination with cytarabine (100–200 mg/m<SUP>2</SUP>/d × 7d). Fifty-three patients showing persistent leukemia on interim bone marrow examination received a second course of induction chemotherapy comprising 2 days of daunorubicin (45 mg/m<SUP>2</SUP>/d) or IDA (8 or 12 mg/m<SUP>2</SUP>/d) in addition to 5 days of cytarabine. Complete remission (CR) rates were 77.3%, 56.9%, and 69.7% for HD-DN, SD-DN, and IDA, respectively (<I>P</I> = 0.101; HD-DN <I>vs.</I> SD-DN, <I>P</I> = 0.036; HD-DN <I>vs.</I> IDA, <I>P</I> = 0.453; IDA <I>vs.</I> SD-DN, <I>P</I> = 0.237). The HD-DN showed higher overall survival (OS) and event-free survival (EFS) than SD-DN and IDA: the differences between HD-DN and SD-DN (<I>P</I> = 0.009 for OS and <I>P</I> = 0.010 for EFS) were statistically significant.</P> <P>Results of <I>in vitro</I> studies using <I>FLT3</I>-ITD-mutated cell lines supported these findings. In conclusion, HD-DN improved the CR rate, OS, and EFS of <I>FLT3</I>-ITD-mutated AML patients. HD-DN also tended to yield better outcomes than IDA, though the difference was not significant. The superiority of HD-DN over IDA should be confirmed in future studies.</P> <P><B>Highlights</B></P> <P> <UL> <LI> <I>FLT3</I>-ITD-mutated AML patients benefited from high-dose daunorubicin. </LI> <LI> High-dose daunorubicin seems to yield better results than idarubicin. </LI> <LI> The results of <I>in vitro</I> studies support these findings. </LI> </UL> </P>